RESUMO
Com a aparição do vírus de inmunodeficiência humana (VIH), a prevalência de toxoplasmosis tem aumentado demais. Em dos pacientes com o síndrome de inmunodeficiência, a toxoplasmosis é a principal causa de morte. A incidência, de anticorpos nesse tipo de pacientes depende da prevalência da população onde se apresenta a doença. O método de Enzima Inmuno Ensaio absorvemnte (ELISA) foi aplicado a 92 pacientes para determinar si eram positivos a anticorpos anti-Toxoplasma IgG e IgM. O resultado foi: 46 (50.5%) foram seropositivos e un caso apresentou anticorpos IgM. D estos 92 pacientes, 53 apresentavam o virus de inmunodeficiência humana (HIV) y 39 tinham SIDA. A determinação e o "monitoreo" de anticorpos anti-Toxoplasma em pacientes com HIV é indispensável, pois uma taxa elevada destos pacientes pode desenvolver a toxoplasmosis cerebral, a causa principal de morte nessos pacientes.
With the emergence of the human immunodeficiency virus (HIV), in patients with acquired immunodeficiency syndrome (AIDS), Toxoplasma gondii has arisen as an important opportunist pathogenic agent, especially in the central nervous system, being the most common cause of intracerebral lesions. The incidence of Toxoplasma gondii in HIV-infected patients depends principally on the existence of latent Toxoplasma parasitosis in the population affected. Through the enzyme-linked immunosorbent assay (ELISA), IgG and IgM anti-Toxoplasma antibodies were found in 92 patients of which 46 (50.0%) were IgG seropositive, and only one case (1.0%) had IgM antibodies. Of the 92 patients: 53 were HIV seropositives and 39 had AIDS. The detection and monitoring of anti-Toxoplasma antibodies in HIV patients is essential, since in this group there is a high percentage risk of developing cerebral toxoplasmosis, which is the second cause of death in this type of patients.
Assuntos
Adolescente , Adulto , Idoso , Animais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anticorpos Antiprotozoários/sangue , HIV-1 , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Infecções Oportunistas Relacionadas com a AIDS/imunologia , Toxoplasma/imunologia , Toxoplasmose/imunologia , Distribuição por Idade , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , México/epidemiologia , Prevalência , Estudos Soroepidemiológicos , Toxoplasmose/epidemiologiaRESUMO
Virend (SP-303), a new topical antiviral agent with activity against herpesvirus, was evaluated in a multicenter, double-blind, placebo-controlled Phase II study for safety and effectiveness against recurrent genital herpes lesions in patients with AIDS. The primary endpoints of this study were complete healing of lesions and time to healing. Patients had a history of recurrent genital or anogenital herpes with at least one lesion and positive HSV culture at enrollment. Participants received Virend (15% ointment; 24 patients) or matching placebo (21 patients) three times a day for 21 days. Excluding two patients in the Virend group who received an initial treatment but were lost to follow-up, 9 of 22 (41%) patients treated with Virend experienced complete healing of their lesions compared with three (14%) patients in the placebo group (P = 0.053). Viral culture revealed that 50% of Virend-treated patients and 19% of placebo-treated patients became culture-negative during treatment (P = 0.06). Based on these preliminary clinical findings, further evaluation of Virend for topical treatment of genital herpes in patients with AIDS is planned.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antivirais/uso terapêutico , Doenças do Ânus/tratamento farmacológico , Biopolímeros/uso terapêutico , Catequina/análogos & derivados , Herpes Genital/tratamento farmacológico , Herpes Simples/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/patologia , Administração Tópica , Adulto , Antivirais/efeitos adversos , Antivirais/química , Doenças do Ânus/induzido quimicamente , Doenças do Ânus/virologia , Biopolímeros/efeitos adversos , Biopolímeros/química , Catequina/efeitos adversos , Catequina/química , Catequina/uso terapêutico , Método Duplo-Cego , Feminino , Seguimentos , Herpes Genital/complicações , Herpes Genital/virologia , Herpes Simples/complicações , Herpes Simples/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Estrutura Molecular , Dor/tratamento farmacológico , Fatores de Tempo , Eliminação de Partículas ViraisRESUMO
With the emergence of the human immunodeficiency virus (HIV), in patients with acquired immunodeficiency syndrome (AIDS), Toxoplasma gondii has arisen as an important opportunist pathogenic agent, especially in the central nervous system, being the most common cause of intracerebral lesions. The incidence of Toxoplasma gondii in HIV-infected patients depends principally on the existence of latent Toxoplasma parasitosis in the population affected. Through the enzyme-linked immunosorbent assay (ELISA), IgG and IgM anti-Toxoplasma antibodies were found in 92 patients of which 46 (50.0%) were IgG seropositive, and only one case (1.0%) had IgM antibodies. Of the 92 patients: 53 were HIV seropositives and 39 had AIDS. The detection and monitoring of anti-Toxoplasma antibodies in HIV patients is essential, since in this group there is a high percentage risk of developing cerebral toxoplasmosis, which is the second cause of death in this type of patients.
